NCT00215423
Completed
Phase 2
Study in Patients With COPD
Dey1 site in 1 country49 target enrollmentSeptember 22, 2005
DrugsFormoterol Fumarate
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Dey
- Enrollment
- 49
- Locations
- 1
- Primary Endpoint
- Measure of lung function
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of COPD
- •History of cigarette smoking
Exclusion Criteria
- •Clinical diagnosis of asthma
- •Significant pulmonary disease other than COPD
- •Other significant major organ disease(s)
Outcomes
Primary Outcomes
Measure of lung function
Secondary Outcomes
- Change in lung function, as well as vital signs
- Physical Exam results, adverse event reporting, etc
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study in Patients With COPDCOPDNCT00215384Dey35
Completed
Phase 3
Study in Patients With COPDCOPDNCT00215449Dey690
Completed
Phase 2
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)COPDNCT00098228Novartis Pharmaceuticals686
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215358Dey32
Completed
Phase 2
Study in Patients With AsthmaAsthmaNCT00215371Dey32